Adaptive Biotechnologies (ADPT) Tops Q4 EPS by 2c, provides guidance

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q4 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $47.46 million versus the consensus estimate of $46.15 million.

2025 Financial Guidance

Adaptive Biotechnologies expects full year revenue for the MRD business to be between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.

We expect full year total company operating expenses, including cost of revenue, to be between $340 million and $350 million.

We expect full year total company cash burn to be between $60 million and $70 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Stifel Downgrades Weave Communications Inc (WEAV) to Hold
• Venu Holding (VENU) PT Lowered to $8.70 at Freedom Broker